Trinity Biotech faces Nasdaq delisting risk, updates diagnostics transformation

Trinity Biotech plc filed a 6-K on August 28, 2026 detailing updates to its diagnostics business alongside a corporate update on its Nasdaq listing status.

On the listing front, the company disclosed that it received a deficiency letter on February 19, 2026 from Nasdaq's Listing Qualifications Department notifying it that the market value of publicly held shares had remained below the $15 million minimum required under Listing Rule 5450(b)(3)(c).¹ The company was granted a 180-day extension, until August 18, 2026, to regain compliance.¹ On August 28, 2026, Trinity received a staff determination letter stating it had not regained compliance by that deadline, and that absent a timely hearing request, its securities would be subject to suspension or delisting.¹ The company said it intends to timely request a hearing before the Nasdaq Hearings Panel.¹ A hearing request automatically stays any suspension or delisting action, and the Panel has authority to grant an extension not to exceed February 24, 2027.¹

On the operating side, Trinity said Jordi Romero has joined the company as Head of Commercial Operations for Europe.¹ The company also reported completion of the rollout of its upgraded HbA1c column system in three of its largest international markets.¹ On manufacturing, Trinity said it completed manufacture of approximately 9 million TrinScreen HIV tests under its new outsourced model and has begun manufacturing Uni-Gold HIV using the same structure.¹ On its pipeline, the company noted it received a European patent covering blood pressure-related metrics in its PrePsia early preeclampsia prediction platform, bringing its total PrePsia-related patents in Europe and the U.S. to nine.¹